Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eeva Piitulainen

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
COPD|May 5, 2015
The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiencyEeva Piitulainen, Hanan A Tanash
Lakartidningen|March 1, 2008
[Alpha 1-antitrypsin and therapeutic evidence]Eeva Piitulainen, Claes-Göran Löwfdahl
Journal of Gastroenterology|January 26, 2019
Liver disease in adults with severe alpha-1-antitrypsin deficiencyHanan A Tanash, Eeva Piitulainen
Investigative Ophthalmology & Visual Science|October 22, 2008
Dark adaptation during systemic hypoxia induced by chronic respiratory insufficiencyJoakim Thylefors, Eeva Piitulainen, Ulf Havelius
Scientific Reports|January 12, 2026
COVID-19 outcomes in individuals with severe alpha-1 antitrypsin deficiency in SwedenSuneela Zaigham, Eeva Piitulainen, Hanan Tanash
Respiratory Medicine|May 29, 2007
Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiencyElisabeth Bernspång, Tomas Sveger, Eeva Piitulainen
International Journal of Chronic Obstructive Pulmonary Disease|January 13, 2022
The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by ScreeningAdriana-Maria Hiller, Eeva Piitulainen, Hanan Tanash
International Journal of Chronic Obstructive Pulmonary Disease|February 17, 2017
Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 yearsEeva Piitulainen, Behrouz Mostafavi, Hanan A Tanash
International Journal of Chronic Obstructive Pulmonary Disease|March 19, 2019
Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 yearsBehrouz Mostafavi, Eeva Piitulainen, Hanan A Tanash
European Journal of Clinical Pharmacology|May 3, 2003
Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsinEeva Piitulainen, Elisabeth Bernspång, Sven Björkman, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
COPD|May 5, 2015
The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiencyEeva Piitulainen, Hanan A Tanash
Lakartidningen|March 1, 2008
[Alpha 1-antitrypsin and therapeutic evidence]Eeva Piitulainen, Claes-Göran Löwfdahl
Journal of Gastroenterology|January 26, 2019
Liver disease in adults with severe alpha-1-antitrypsin deficiencyHanan A Tanash, Eeva Piitulainen
Investigative Ophthalmology & Visual Science|October 22, 2008
Dark adaptation during systemic hypoxia induced by chronic respiratory insufficiencyJoakim Thylefors, Eeva Piitulainen, Ulf Havelius
Scientific Reports|January 12, 2026
COVID-19 outcomes in individuals with severe alpha-1 antitrypsin deficiency in SwedenSuneela Zaigham, Eeva Piitulainen, Hanan Tanash
Respiratory Medicine|May 29, 2007
Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiencyElisabeth Bernspång, Tomas Sveger, Eeva Piitulainen
International Journal of Chronic Obstructive Pulmonary Disease|January 13, 2022
The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by ScreeningAdriana-Maria Hiller, Eeva Piitulainen, Hanan Tanash
International Journal of Chronic Obstructive Pulmonary Disease|February 17, 2017
Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 yearsEeva Piitulainen, Behrouz Mostafavi, Hanan A Tanash
International Journal of Chronic Obstructive Pulmonary Disease|March 19, 2019
Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 yearsBehrouz Mostafavi, Eeva Piitulainen, Hanan A Tanash
European Journal of Clinical Pharmacology|May 3, 2003
Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsinEeva Piitulainen, Elisabeth Bernspång, Sven Björkman, et al.
Pageof 7